Stephen V Liu: Is immunotherapy effective for HER2 mutant NSCLC?

Stephen V Liu shared on X a recent paper by Yuki Kato et al. titled “Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia” published in Lung Cancer Journal.

Authors: Yuki Kato et al.

“Is immunotherapy effective for HER2 mutant NSCLC? Retrospective look Lung Cancer Journal from LC-SCRUM at 402 pts with HER2mt NSCLC: 95 had chemo-IO (PFS 8.5m, OS 31.1m) and 173 had chemo alone (PFS 6.3m, OS 23.3m). I suspect targeted therapy here soon.”

More posts featuring Stephen V Liu on OncoDaily.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr.

Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.